Literature DB >> 7797077

Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.

C F Eisenbeis1, H Singh, U Storb.   

Abstract

The immunoglobulin light-chain gene enhancers E kappa 3', E lambda 2-4, and E lambda 3-1 contain a conserved cell type-specific composite element essential for their activities. This element binds a B cell-specific heterodimeric protein complex that consists of the Ets family member PU.1 and a second factor (NF-EM5), whose participation in the formation of the complex is dependent on the presence of DNA-bound PU.1. In this report we describe the cloning and characterization of Pip (PU.1 interaction partner), a lymphoid-specific protein that is most likely NF-EM5. As expected, the Pip protein binds the composite element only in the presence of PU.1; furthermore, the formation of this ternary complex is critically dependent on phosphorylation of PU.1 at serine-148. The Pip gene is expressed specifically in lymphoid tissues in both B- and T-cell lines. When coexpressed in NIH-3T3 cells, Pip and PU.1 function as mutually dependent transcription activators of the composite element. The amino-terminal DNA-binding domain of Pip exhibits a high degree of homology to the DNA-binding domains of members of the interferon regulatory factor (IRF) family, which includes IRF-1, IRF-2, ICSBP, and ISGF3 gamma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797077     DOI: 10.1101/gad.9.11.1377

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  137 in total

1.  Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions.

Authors:  M A Ortiz; J Light; R A Maki; N Assa-Munt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

3.  DNA binding and transcription activation by chicken interferon regulatory factor-3 (chIRF-3).

Authors:  C E Grant; D L May; R G Deeley
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

4.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.

Authors:  Jirí Nehyba; Radmila Hrdlicková; Joan Burnside; Henry R Bose
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

6.  Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors.

Authors:  B Lubyova; P M Pitha
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 7.  Transcriptional regulation of myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

8.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

9.  Mechanisms of autoinhibition of IRF-7 and a probable model for inactivation of IRF-7 by Kaposi's sarcoma-associated herpesvirus protein ORF45.

Authors:  Narayanan Sathish; Fan Xiu Zhu; Ellis E Golub; Qiming Liang; Yan Yuan
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

10.  Th9 cell development requires a BATF-regulated transcriptional network.

Authors:  Rukhsana Jabeen; Ritobrata Goswami; Olufolakemi Awe; Aishwarya Kulkarni; Evelyn T Nguyen; Andrea Attenasio; Daniel Walsh; Matthew R Olson; Myung H Kim; Robert S Tepper; Jie Sun; Chang H Kim; Elizabeth J Taparowsky; Baohua Zhou; Mark H Kaplan
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.